Phase II trial of idarubicin, fludarabine, Ara-C, and filgrastim filgrastim (G-CSF) (Ida-FLAG) for treatment of poor prognosis acute myeloid leukemia (AML).

被引：0
|
作者：
Wickramanayake, PD [1 ]
Steinmetz, HT [1 ]
Katay, I [1 ]
Glasmacher, A [1 ]
Staib, P [1 ]
Diehl, V [1 ]
机构：
[1] UNIV HOSP KOLN,DEPT INTERNAL MED 1,COLOGNE,GERMANY
来源：
BLOOD | 1995年 / 86卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3009 / 3009
页数：1
相关论文
共 50 条
  • [1] PHASE-II TRIAL OF IDARUBICIN, FLUDARABINE, CYTIDINE ARABINOSIDE (ARA-C), AND FILGRASTIM (G-CSF) (IDA-FLAG) FOR TREATMENT OF POOR-PROGNOSIS ACUTE MYELOID-LEUKEMIA (AML)
    WICKRAMANAVAKE, PD
    STEINMETZ, HT
    KATAY, I
    GLASMACHER, A
    NEUFANG, A
    STAIB, P
    SCHWONZEN, M
    DIEHL, V
    BLOOD, 1994, 84 (10) : A618 - A618
  • [2] Phase II study of Idarubicine, Fludarabine, ARA-C, and G-CSF (IDA-Flag) for treatment of refractory, relapsed or secondary acute myeloid leukemia
    Steinmetz, HT
    Staib, P
    Glasmacher, A
    Neufang, A
    Katay, I
    Diehl, V
    Wickramanayake, PD
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 821 - 821
  • [3] Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML
    H. T. Steinmetz
    A. Schulz
    P. Staib
    C. Scheid
    A. Glasmacher
    A. Neufang
    J. Franklin
    H. Tesch
    V. Diehl
    P. Dias Wickramanayake
    Annals of Hematology, 1999, 78 : 418 - 425
  • [4] Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML
    Steinmetz, HT
    Schulz, A
    Staib, P
    Scheid, C
    Glasmacher, A
    Neufang, A
    Franklin, J
    Tesch, H
    Diehl, V
    Wickramanayake, PD
    ANNALS OF HEMATOLOGY, 1999, 78 (09) : 418 - 425
  • [5] Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia
    Yalman, N
    Sarper, N
    Devecioglu, Ö
    Anak, S
    Eryilmaz, E
    Can, M
    Yenilmez, H
    Agaoglu, L
    Gedikoglu, G
    TURKISH JOURNAL OF PEDIATRICS, 2000, 42 (03) : 198 - 204
  • [6] Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia
    Montillo, M
    Mirto, S
    Petti, MC
    Latagliata, R
    Magrin, S
    Pinto, A
    Zagonel, V
    Mele, G
    Tedeschi, A
    Ferrara, F
    AMERICAN JOURNAL OF HEMATOLOGY, 1998, 58 (02) : 105 - 109
  • [7] IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial
    Fleischhack, G
    Hasan, C
    Graf, N
    Mann, G
    Bode, U
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (03) : 647 - 655
  • [8] Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia
    Parker, JE
    Pagliuca, A
    Mijovic, A
    Cullis, JO
    Czepulkowski, B
    Rassam, SMB
    Samartunga, IR
    Grace, R
    Gover, PA
    Mufti, GJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (04) : 939 - 944
  • [9] A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F-ara-A) and cytarabine (ara-C) for refractory or recurrent pediatric acute myeloid leukemia (AML)
    Leahey, A
    Kelly, K
    Rorke, LB
    Lange, B
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1997, 19 (04) : 304 - 308
  • [10] Multidrug resistance expression and proliferative studies in poor risk acute myeloid leukemia treated with the FLAG (G-CSF plus fludarabine and Ara-C) regimen
    Tafuri, A
    DeFelice, L
    Petrucci, MT
    Mascolo, MG
    Ricciardi, MR
    Ciliberti, C
    Martelli, MP
    Petti, MC
    CYTOKINES AND MOLECULAR THERAPY, 1995, 1 (04): : 301 - 307
12345